WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

Mayo Clinic

Status: Enrolling

Conditions: Sarcoma; Lymphoma

Treatments: Other: 6 minute walk test; Procedure: Echocardiogram; Procedure: Electrocardiogram; Procedure: Biospecimen collection; Other: Grip strength test; Other: Apple Watch; Other: Questionnaires; Other: Cardio-pulmonary exercise test; Procedure: LVEF echocardiogram

Study type: Interventional

Funder types: Other

Identifiers

NCT07058064

25-002911 (Other Identifier)

HT94252510309 (Other Grant/Funding Number)

NCI-2025-04631 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.

Enrollment: 250 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ability to understand study procedures and being willing to comply with them for the entire study length
• diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy

Exclusion criteria

• LVEF <50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm
• Unwilling or unable to give written informed consent
• Participants who have opted out of the Minnesota Research Authorization

Trial design

Primary purpose: Screening

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

250 participants in 2 patient groups

Cross-sectional Arm

Active Comparator group

Description:

Lymphoma and sarcoma cancer survivors will be seen at one time point, 1 year after completion of anthracycline-based therapy.

Treatment:

Procedure: LVEF echocardiogram

Other: Questionnaires

Procedure: Biospecimen collection

Procedure: Echocardiogram

Procedure: Electrocardiogram

Longitudinal Arm

Experimental group

Description:

Lymphoma and sarcoma cancer survivors will be seen before the start of anthracycline-based therapy and followed every three months up to 1 year after completion of therapy. Longitudinal participants will have the option of recording ECG and cardio fitness data through an Apple Watch from before up to 1 year post anthracycline treatment.

Treatment:

Procedure: LVEF echocardiogram

Other: Cardio-pulmonary exercise test

Other: Questionnaires

Other: Grip strength test

Other: Apple Watch

Procedure: Biospecimen collection

Procedure: Echocardiogram

Procedure: Electrocardiogram

Other: 6 minute walk test